5 completed, 2 recruiting. 6 Phase 1, 1 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 6 | Completed 4, Recruiting 2 |
| Phase 2 | 1 | Recruiting 1 |
| Phase 3 | 1 | Completed 1 |
Follow Zhejiang ACEA Pharmaceutical Co. Ltd.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate the STI-8591 in Subjects With Advanced Acute Myeloid Leukemia (AML) STI-8591 - AML, Adult | Phase 1 | Recruiting | Zhejiang ACEA Pharmaceutical Co. Ltd. | 84 | 2023-12-08 | 2025-03-17 |
| A Bioequivalence Trial of Fasting Single Oral STI-1558 Capsule in Healthy Chinese Subjects STI-1558 - COVID-19 | Phase 1 | Completed | Zhejiang ACEA Pharmaceutical Co. Ltd. | 32 | 2023-09-28 | 2023-12-13 |
| [14C] Study on Mass Balance and Biotransformation of STI-1558 in Healthy Chinese Adult Male Subjects [14C]STI-1558 - COVID-19 | Phase 1 | Completed | Zhejiang ACEA Pharmaceutical Co. Ltd. | 6 | 2023-05-15 | 2023-12-07 |
| Safety and Efficacy Study of An Anti-CD38 Antibody Drug Conjugate in Relapsed or Refractory Multiple Myeloma STI-6129 - Relapsed or Refractory Multiple Myeloma | Phase 1 / Phase 2 | Recruiting | Zhejiang ACEA Pharmaceutical Co. Ltd. | 84 | 2023-02-09 | 2025-08-15 |
| Study to Assess the Efficacy and Safety of STI-1558 in Adult Subjects With Mild or Moderate (COVID-19) STI-1558, STI-1558 placebo - COVID-19 | Phase 3 | Completed | Zhejiang ACEA Pharmaceutical Co. Ltd. | 1218 | 2023-02-08 | 2024-05-14 |
| A Study to Evaluate the Relative Bioavailability of STI-1558 and the Effect of Itraconazole and Rifampin on the Pharmacokinetics of STI-1558 STI-1558, Itraconazole, Rifampin - COVID-19 Pneumonia | Phase 1 | Completed | Zhejiang ACEA Pharmaceutical Co. Ltd. | 37 | 2023-01-04 | 2023-12-07 |
| Safety and Efficacy Study of STI-1558 in Healthy Adults and SARS-CoV-2-Positive Patients STI-1558 - SARS-CoV-2 Infection | Phase 1 | Completed | Zhejiang ACEA Pharmaceutical Co. Ltd. | 79 | 2022-09-16 | 2023-08-14 |
COVID-19 (4) · Leukemia, Myeloid, Acute (1) · Multiple Myeloma (1) · Recurrence (1)
STI-1558 (4) · Itraconazole (1) · Rifampin (1)
China (7)